Study: Critical Diagnostics heart failure biomarker beats out BG Medicine test; BioMarker Strategies lands $1.5M grant for melanoma diagnostic;

> Critical Diagnostics published a study finding that its myocardial fibrosis biomarker, ST2, for long-term heart failure risk performed better than BG Medicine's Galectin-3. Release

> Life Technologies ($LIFE) says it will distribute Advanced Cell Diagnostics' fluorescent RNAscope biomarkers technology to the research market, according to GenomeWeb. Item (sub. req.) 

> Baltimore, MD-based BioMarker Strategies has won a $1.5 million Small Business Innovation Research Phase II award from the National Cancer Institute to further develop its companion diagnostic for melanoma. Item (sub. req.)

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.